Fortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Debt to equity
Fortrea Holdings Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 2.0×, up 0.1× from fiscal 2025 (1.9×). Over the past ten years it has ranged from 0.0× (fiscal 2021) to 1.9× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 1.9× | 126.35% |
| FY2024 | 0.8× | (11.13%) |
| FY2023 | 0.9× | 4,840.43% |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 2.0× | (1.43%) |
| Jun 2026 | 2.0× | 0.40% |
| Mar 2026 | 2.0× | 7.22% |
| Dec 2025 | 1.9× | (3.68%) |
| 15 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| BHVN Biohaven Ltd. compare | −2.7× |
| VIR Vir Biotechnology, Inc. compare | 0.0× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.0× |
| ZYME Zymeworks Inc. compare | 0.0× |
| IMNM Immunome, Inc. compare | 0.0× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 0.1× |
| SRPT Sarepta Therapeutics, Inc. compare | 0.6× |
| REPL Replimune Group, Inc. compare | 0.6× |
| FTRE Fortrea Holdings Inc. | 2.0× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)